\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
Several Brussels based R&I Liaison Offices (namely Swisscore, Helmholtz and PolSCA) are organising an event to brainstorm about the future Brain Health Partnership.
The event will bring together prominent researchers, policymakers, and key stakeholders to discuss the future of brain health research in Europe. The focus will be on fostering interdisciplinary collaboration, advancing policy, and addressing pivotal challenges within the field. Highlights will include the transformative potential of the Brain Health European Partnership, which aims to translate scientific insights into effective health solutions.
Deadline for registration is 7 November 2024.
Further details on the agenda and how to register is availble on this link: PolSCA website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Research Infrastructures Culture and society Climate, Energy, Mobility
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
